News Focus
News Focus
Followers 87
Posts 5742
Boards Moderated 0
Alias Born 03/07/2014

Re: Rkmatters post# 6091

Tuesday, 06/23/2015 10:38:31 AM

Tuesday, June 23, 2015 10:38:31 AM

Post# of 35699
Not sure if she will be speaking of TPIV but if she mentions them that in itself will be a catalyst for the company.
As for the Ph1 data. Patients were cancer free for 9 months. Three months prior to the trial and the six months that they were treated with the vaccine. That's great. I imagine they will try to increase the time frame during the ph 2 trial. 9 months is impressive. Also 19 out of 20 showed immune response. This is great news. They didn't mention much on toxicity either. Let's hope they collaborate with a company like ZIOP who currently has a ph 1 in breast cancer with CAR T therapy. They also have an off on switch for toxicity. The only company with this switch. It's from Intrexon and is called the Rheoswitch.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MRKR News